Clinical Trials · NCT06732245
Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese
- Phase
- Phase 2
- Recruitment status
- Not Yet Recruiting
- Sponsor
- Biomed Industries, Inc.
- Enrollment
- 224
- Start date
- Aug 2026
- Locations
- 17 sites, 3 countries
- Primary endpoint
- Change from baseline in body weight at 48 weeks